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ABSTRACT
Introduction: Few innovative anti-microbial products have been brought to market in recent years to
combat the global multidrug resistant-tuberculosis (MDR-TB) epidemic. Bedaquiline, a novel oral
diarylquinoline, was approved by the US FDA as a part of combination therapy in adults with
pulmonary MDR-TB based on phase II trials.
Area covered: Pubmed searches were conducted using search terms bedaquiline, diarylquinoline,
R207910, and TMC207 was performed. Supplementary sources included World Health Organization,
Clinicaltrial.gov, US Food and Drug Administration. Bedaquiline is an ATP synthase inhibitor specific for
M. tuberculosis and some nontuberculous mycobacteria. It is metabolized by CYP3A4 and it’s drug
exposure can be influenced by inducers and inhibitors of this enzyme. Phase II studies showed promising
results on efficacy of bedaquiline when being used in combination with a background regimen for MDR-
TB. Main safety concerns include QTc prolongation and hepatotoxicity. Phase III trials are ongoing to
confirm efficacy findings from phase II studies and provide additional evidence of safety and efficacy.
Expert commentary: Critical data for long-term efficacy and safety are incomplete and scarce, support-
ing the cautious use of bedaquiline.
ARTICLE HISTORY
Received 1 April 2016












Tuberculosis (TB) now ranks alongside HIV as a leading
infectious cause of death worldwide and is caused by infec-
tion with Mycobacterium tuberculosis (MTB) [1]. In 2014, an
estimated 9.6 million new TB cases occurred globally,
480,000 of which being affected by multidrug resistance
tuberculosis (MDR-TB) defined as TB resistant to both iso-
niazid and rifampicin. An estimated 190,000 died from MDR-
TB in 2014 alone [1]. MDR-TB may arise from poor adher-
ence which often occurs during the long and burdensome
treatment of TB and may lead to the development of resis-
tance and subsequent treatment failures [1]. Treatment of
MDR-TB is more challenging, with second-line drugs being
less effective and more toxic than isoniazid and rifampicin-
based regimens. It becomes even more complex when MDR
strains with additional resistance have emerged. Extensively
drug-resistant tuberculosis (XDR-TB), defined as MDR-TB
plus resistance to a fluoroquinolone and an injectable sec-
ond-line drug, has recently been reported at an alarming
rate and is even more threatening to TB control and elim-
ination [1]. MDR/XDR-TB can be transmitted and cause pri-
mary infections. Treatment success rates in patients with
MDR/XDR-TB are low. In 1269 XDR-TB patients reported in
40 countries, only 22% completed their treatment
successfully and 35% of the patients died. The treatment
is long, side effects and adverse events (AEs) are common,
and the treatment and management of the cases is expen-
sive and burdensome [1]. The need for new drugs against
TB thus becomes increasingly urgent.
Bedaquiline, formerly known as TMC207 or R207910, is a
diarylquinoline with a novel mechanism of action [2]. It is the
first new anti-TB drug approved for the treatment of TB in the
United States (US) (2012) and Europe (2014) since the approval
of rifampicin in 1971 in the US. Both bedaquiline and delama-
nid, the other anti-TB drug recently approved, have been
registered for MDR-TB treatment (delamanid only in Europe).
Current interim guidance for its use provided by the World
Health Organization (WHO) is based on limited data collected
from phase II trials [3]. Although bedaquiline showed obvious
advantages with action against MDR-MTB strains, its AEs,
drug–drug interactions, and the emergence of drug-resistant
MTB strains should be held in consideration. Long-term safety
data of this drug are rare and no phase III studies have been
completed to date to make a definite conclusion on safety.
2. Overview of drug treatment for MDR-TB
Whereas the standard treatment regimen of drug-suscep-
tible (DS) TB is a 2-month regimen of isoniazid, rifampicin,
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pyrazinamide, and ethambutol, followed by a 4-month
regimen of isoniazid and rifampicin, MDR-TB requires
intensive, more prolonged, more toxic, and complex treat-
ment regimens, with up to 6 second-line agents drugs,
including injectable anti-TB agents (see Table 1). The
total treatment duration of MDR-TB is 20 months for
most patients, and even up to 2 years, depending on the
patient’s response to therapy [4,5]. The landscape of TB
drug development has evolved dramatically over the past
10 years, and novel drugs are entering phase III trials for
the treatment of MDR-TB, including bedaquiline and dela-
manid [6,7]. These trials aim to both shorten and simplify
the treatment of drug-resistant TB. Some repurposed drugs
like linezolid, clofazimine, amoxicillin/clavulanate, imipe-
nem/cilastin, and meropenem have demonstrated in vitro
or in vivo activity and safety in humans for the treatment
of MDR-TB and are classified as group 5 MDR-TB drugs by
the WHO; however, they are not licensed for treatment of
MDR-TB [4].
3. Introduction to the drug
Bedaquiline defines a new class of antimycobacterial com-
pounds, the diarylquinolines due to its novel mode of
action. It targets mycobacterial adenosine 5′-triphosphate
(ATP) synthase, which is a critical enzyme for the generation
of energy in mycobacteria [2]. Bedaquiline binds to this
enzyme at the central region of its c subunit, halting the
energy production process and inhibiting the mycobacterial
reproduction, resulting in bactericidal effects for both
replicating and nonreplicating (dormant) tubercle bacilli
[8–10]. Some mutations in the c subunit can lead to resis-
tance to bedaquiline [9]. The distinct target of bedaquiline
minimizes the potential for cross-resistance with existing
anti-TB agents. Currently, no other drugs of the same phar-
macological class are available.
4. Chemistry
The chemical name of bedaquiline (Figure 1) is (1R,2S)-1-(6-
bromo-2-methoxy-3-quinolinyl)-4-dimethylamino)-2-(1-
naphthalenyl)-1-phenyl-2-butanol. It is compounded with
fumaric acid (1:1) as bedaquiline fumarate [2].
Table 1. WHO anti-TB drugs [4].
Group Anti-TB drug Note
Group 1. First-line drugs Isoniazid, Rifampicin,
Pyrazinamide, Rifabutin,
Rifapentine
Rifabutin and rifapentine have similar microbiological activity
as rifampicin. Rifabutin is not on the WHO list of essential
medicines; however, it is used routinely in patients on
protease inhibitors in many settings
Rifapentine is part of a latent TB infection and active TB
treatment in some countries but to date is not part of any
WHO-endorsed treatment regimens
Group 2. Injectable anti-TB drugs Streptomycin, Kanamycin,
Amikacin, Capreomycin
There are high rates of streptomycin resistance in strains of
MDR-TB; thus, streptomycin is not considered a second-line
anti-TB injectable agent
Group 3. Fluoroquinolones Levofloxacin, Moxifloxacin,
Gatifloxacin
Oxifloxacin is considered a weaker agent with less anti-TB
activity than other fluoroquinolones and has been removed
as a choice in Group 3 drugs
Gatifloxacin can have severe side effects including serious
diabetes (dysglycemia). It has been removed from the
market of a number of countries as safer alternatives
whenever possible are available for the diseases for which
the drug is labeled. However, it is widely used as a generic
and is part of the 9-month Bangladesh regimen for MDR-TB




Terizidone has limited program data and effectiveness data as
compared to cycloserine
Group 5. Anti-TB drugs with limited data on efficacy and/or
long-term safety in drug-resistance TB treatment (this







Clavulanate is recommended as an adjunctive agent to
imipenem/cilastatin and meropenem
Limited data on the role of thioacetazone and clarithromycin in
MDR-TB treatment have resulted in many experts not
including these drugs as options for Group 5
TB: Tuberculosis.
Figure 1. Structure of bedaquiline.
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5. Pharmacodynamics
Bedaquiline exhibits potent in vitro activity against multiple
strains of MTB, including DS, MDR, and XDR MTB strains with a
minimal inhibitory concentration (MIC) of 0.03–0.12 mg/L.
Dormantmycobacteria have lower ATP supplies and are therefore
more expected to be more vulnerable to further ATP depletion by
bedaquiline even at nanomolar concentrations. However, this
hypothesis needs to be comfirmed. Bedaquiline is active within
macrophages and it has remarkable sterilizing capacity that
makes it an attractive drug for MDR-TB treatment [9]. The drug
also possesses a good activity againstMycobacterium avium com-
plex, Mycobacterium leprae, Mycobacterium bovis, Mycobacterium
marinum, Mycobacterium kansasii, Mycobacterium fortuitum, and
Mycobacterium szulgai and perhaps even more nontuberculous
mycobacteria [8–11].
The bactericidal activity of bedaquiline was demonstrated in a
study on early bactericidal activity (EBA) in treatment-naïve
patients with sputum smear-positive pulmonary TB. Oral once
daily administration of bedaquiline has bactericidal activity at a
dose of 400 mg when administered as monotherapy for 7 days
with a modest but statistically significant change in CFU (colony-
forming units). Bactericidal activity at a dose of 400mg started late
but was of similar magnitude on days 4–7. The overall reduction of
−0.77 log10 CFU over the 7-day period failed to match the high
expectations fostered by the promising preclinical results [12]. A
later randomized, controlled trial in MDR-TB patients treated with
bedaquiline-containing regimens confirmed the moderate effect
of bedaquiline up to 7 days. This trial also showed that bedaquiline
appreciably accelerated the bactericidal activity of background
regimen for up to 4 weeks [13]. This emphasizes the time-depen-
dent activity of bedaquiline and its unique action mode, involving
disruption of energy homeostasis, whereas bedaquiline and its N-
desmethyl metabolite was reported to display concentration-
dependent bactericidal activity in the murine model [14]. The
results of this study suggest that future EBA studies with new
anti-TB agents need to be extended to 14 days [13]. In a dose-
ranging 14-day EBA study, all four bedaquiline dose groups (100,
200, 300, and 400 mg), preceded by loading doses, showed sig-
nificant activity and this activity continued to the end of the 14-
day evaluation period. Increasing the doses of bedaquiline subse-
quently improved the EBA [15]. The loading doses were required
to counter extensive tissue distribution and to achieve adequate
exposures. Recently, the delayed bactericidal response of MTB to
bedaquiline was explained by a metabolic remodeling in myco-
bacteria triggered by bedaquiline exposure, thereby enabling
transient bacterial survival [16]. In a TB murine model, the intra-
cellular activity of bedaquiline was demonstrated to be greater
than its extracellular activity due to the shorter or absent prelimin-
ary static phase [17].
Synergistic effects of bedaquiline and some other drugs have
been studied in murine TB models. It is shown that bedaquiline
enhances the antibacterial activity of second-line drugs [18].
Furthermore, bedaquiline synergized with pyrazinamide against
MTB in mice after only 2 months of therapy [19], and the addition
of bedaquiline to first- or second-line drug regimens accelerated
clearance of bacilli [18]. This may help shorten treatment regimens
for susceptible or MDR-TB. Concomitant treatment with verapamil
in vitro reduced the MIC of bedaquiline 8–16-fold [20]. However,
verapamil did not reduce the MIC of bedaquiline in mice or alter
efflux-based resistance [21]. The adjunctive use of verapamil was
documented to increase the bactericidal activity of bedaquiline in
a mouse model and protected against the development of resis-
tant mutants in vivo. This synergistic effect may be due to efflux
pump inhibition by verapamil, resulting in higher intracellular
drug concentrations. Another approach is that oxazolidinone
might increase activity of novel regimens in a mouse model of
TB containing bedaquiline and pretonamid [22]. Clinical relevance
should be confirmed by intervention studies on TB patients [23].
A dose of 400 mg once daily for 2 weeks followed by 200 mg
thrice weekly in multidrug regimens for MDR-TB achieved
plasma concentrations above 0.6 mg/L throughout the dosing
interval, a target that may reach efficacy similar to 25 mg/kg in
mice. The target average plasma level of 0.6 mg/L was selected
based on a mouse model of TB infection but has not been
validated in humans, so therapeutic concentrations in humans
remain unclear [13]. In a murine model, the bactericidal activity
appeared to be AUC related [14], which is in consistent with the
study in humans, in which bedaquiline plasma concentrations
and bactericidal activity appeared to increase with dose up to
400 mg daily [15]. Results frommurine models reveal that AUC is
the main pharmacokinetic–pharmacodynamic driver for beda-
quiline and is the parameter on which dose optimization should
be based [14]. In TB-infected patients, the majority of the bacter-
icidal efficacy is achieved by bedaquiline but not by its metabo-
lite. It is reported that the N-monodesmethyl metabolite (M2) of
bedaquiline has 4–6 times lower antimycobacterial activity than
bedaquiline but may have a higher risk of toxicity [24].
6. Pharmacokinetics and metabolism
Bedaquiline is well absorbed orally irrespective of doses in
human. The maximum plasma concentration (Cmax) is reached
after 4–6 h (Tmax) of administration. After administration of the
recommended dose of 400 mg/day, the Cmax was 5.5 mg/L,
the AUC0-24 was 65 mg h/L, and so the clearance was around
6.2 L/h. Interestingly, bedaquiline showed a multiphasic dis-
tribution and elimination profile with an exceedingly long
terminal half-life of 5.5 months, owing to a combination of a
long plasma half-life, high tissue penetration (particularly the
organs affected by TB), and long half-life in tissues. This makes
it suitable for intermittent drug administration. However, the
long half-life could pose risk of AEs to patients even after
discontinuation of therapy. The emergence of bedaquiline
resistance due to low and constant exposure could be intro-
duced as a consequence. The volume of distribution in the
central compartment is approximately 164 L with plasma
protein binding over 99.9%. The drug displays a linear phar-
macokinetic profile, in which Cmax and AUC increase propor-
tionally with the dose following single doses of between 10
and 700 mg in healthy subjects and multiple doses of
between 25 and 400 mg once daily in DS or MDR-TB patients.
The half-life is independent of administered dose [2,13,25,26].
The effective half-life is 24 h [2], which is substantially longer
than most other anti-TB drugs. Pharmacokinetics of bedaqui-
line is comparable in healthy subjects and patients with pul-
monary TB [12]. In MDR-TB patients, after 2 weeks of 400 mg
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daily, followed by 6 weeks of treatment with 200 mg 3 times
weekly, mean (±SD) peak, minimum, and steady-state plasma
concentrations of bedaquiline at week 2 were 3.27 ± 1.14,
0.96 ± 0.56, and 1.77 ± 0.70 mg/L, respectively, and at week
8 were 1.66 ± 0.72, 0.62 ± 0.47, and 0.90 ± 0.54 mg/L, respec-
tively. The majority of patients achieved average steady-state
plasma concentrations above the target of 0.60 mg/L through-
out the dosing period [13].
Only phase I metabolism was observed in human. After oral
administration, bedaquiline is rapidly metabolized by CYP3A4 to
form its M2. Subsequently, M2 is further demethylated, likely also
by CYP3A4, to a M3 metabolite with negligible antimycobacterial
activity [26]. Drugs that induce CYP3A4, such as rifampicin, may
decrease the plasma concentrations of bedaquiline, thus poten-
tially reducing its therapeutic effect. Conversely, coadministration
of inhibitors of these enzymes, such as protease inhibitors,
macrolide antibiotics, and azole antifungals, is likely to increase
concentrations of bedaquiline [26,27]. Following coadministra-
tion of bedaquiline with ketoconazole, a strong inhibitor of
CYP3A, AUC and Cmax of bedaquiline increased by 22% and 9%
(day 14 vs. day 11). The modest effects of ketoconazole on
bedaquiline could be misleading. Owing to long terminal half-
life of bedaquiline, steady-state concentrations were not
achieved prior to pharmacokinetic sampling, so full interaction
potential could not be detected during the short-term coadmi-
nistration of ketoconazole. Moreover, the high protein and phos-
pholipids binding of bedaquiline may limit the availability of
bedaquiline for metabolic isoenzymes, leading to a low clearance
and, accordingly, a limited impact of metabolic inhibition [25].
Using nonlinear mixed effect model, lopinavir/ritonavir was
found to decrease the clearance of both bedaquiline to 35%
and M2 to 58% without co-medication. The model predicted
that concomitant administration of lopinavir/ritonavir would
have caused a close to three- and twofold increases in average
steady-state concentration (Css,avg) for bedaquiline and M2,
respectively [28]. The significant increase of bedaquiline exposure
caused by lopinavir/ritonavir was recently confirmed, but its
clinical significance remains unclear [29]. The potential effect of
long-term coadministration of bedaquiline and efavirenz, a
CYP3A inducer, was assessed using a population pharmacoki-
netic model. In healthy adult volunteers, a single dose of efavir-
enz only minimally influenced bedaquiline pharmacokinetics
[30]. However, efavirenz could reduce concentrations of bedaqui-
line and its main metabolite by up to 52% upon chronic coad-
ministration. Dosing adjustments of the standard bedaquiline
regimen and careful monitoring during concomitant use of efa-
virenz can prevent reduced exposure to bedaquiline [31]. No
significant change in pharmacokinetics of bedaquiline was
observed in individuals taking bedaquiline in combination with
nevirapine, so bedaquiline can be coadministered with nevira-
pine without dose adjustments in patients coinfected with HIV
and TB [28]. The coadministration of bedaquiline with rifamycins
or other potent CYP3A inducers is not recommended, even with
dose adjustment, due to the risk of reduced bedaquiline expo-
sure and a consequent loss of therapeutic efficacy [32,33]. No
significant pharmacokinetic interaction with isoniazid, pyrazina-
mide, ethambutol, kanamycin, ofloxacin, or cycloserine was
reported [34]. An overview of the drug-drug interactions is pre-
sented in Table 2.
The main metabolite M2 is primarily excreted in the stool,
with only 1–4% removed in the urine. The extent of N-des-
methylation was dose independent within the dose range
tested. Pharmacokinetics of M2 is also linear over the dose
range of 50–400 mg.
The pharmacokinetics of bedaquiline was not affected by
mild-to-moderate renal impairment (median creatinine clear-
ance 108 mL/min, range 39.8–227 mL/min). There is no need
to adjust bedaquiline dose for patients with moderate hepa-
tic or renal impairment. Caution is recommended for those
with severe renal or liver disease. Age, sex, body weight, and
HIV coinfection in the absence of antiretroviral treatment did
not influence its pharmacokinetics. Subjects of black ethni-
city had lower concentrations of bedaquiline than other
races. Notably, in light of this finding, bedaquiline did not
improve treatment outcomes in one subgroup of people of
African ancestry in a recent clinical trial [26]. To date, no
correlation has been found between drug exposure and out-
come. When taken with food, bedaquiline exposure increases
approximately twofold [9]. A meal containing 22 g of fat
doubled bioavailability of bedaquiline compared to its inges-
tion on an empty stomach. The pharmacokinetics of bedaqui-
line has not yet been studied in pediatric or elderly
populations [26]. Penetration of bedaquiline in cerebrospinal
fluid (CSF) was evaluated in one patient with MDR-TB menin-
gitis; the undetectable low concentration of bedaquiline in
CSF suggested that bedaquiline may be among second-line
anti-TB drugs with poor penetration in CSF and this needs to
be further explored [35].
To facilitate pharmacokinetic study, analytical method for
determination of bedaquiline should be established. A method
described by Rustomjee et al. using a liquid chromatography–
tandem mass spectrometry (LC–MS/MS) show a wide validate
analytical range from 0.001 to 2.000 mg/L for both bedaquiline
and its metabolite. The method is demonstrated to be accurate
and precise for application in PK study [12]. Another simple and
robust LC–MS/MS method without extensive sample processing,
using deuterated bedaquiline as internal standard, was recently
validated [36]. The run time of this method was 2.6 min.
Analytical range was 0.05–6.00 mg/L with acceptable accuracy
and precision for both bedaquiline and M2 [36].
7. Drug resistance
Mutations to bedaquiline have been reported in the literature.
One has to distinguish in vitro observations from clinical
observations and data have to be interpreted carefully.
Initially, mutations in atpE, which encodes for subunit c of
ATP synthase, and in Rv0678 were found to be related to
bedaquiline resistance [11,37]. Five single-point mutations
within the atpE gene included A28V, A63P, I66M, A28P, and
G61A [38]. In a larger study, it was observed that only 28% of
the bedaquiline-resistant MTB bacilli carried mutations in atpE.
The remaining 72% resistant mutant did not harbor any muta-
tions within atpE and this remains unexplained [38]. This result
suggested that at least one additional ATP synthase-indepen-
dent mechanism of resistance to bedaquiline exists [38]. The
apparent rate of mutation to high-level resistance against
bedaquiline decreased with an increased drug concentration.
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No resistant mutants were found at 3 mg/L (100× MIC of
bedaquiline-susceptible MTB) [38]. Cross-resistance between
clofazimine and bedaquiline through upregulation of MmpL5
in MTB was reported [21,39]. Recently, development of
acquired resistance to bedaquiline and delamanid was found
in the context of inadequate MDR-TB and XDR-TB treatment
regimens. This serves a warning for the future rollout of new
anti-TB drugs and emphasizes the need for the appropriate
use of companion drugs when bedaquiline and delamanid are
administered [40]. Although adequate bedaquiline susceptibil-
ity testing procedures [41] are available, a guidance document
has not been established yet [42].
8. Clinical efficacy
8.1. Phase I and phase II studies
From 2005 to 2012, 11 phase I studies in 265 subjects have
been conducted to evaluate pharmacokinetic characteristics,
dosing regimens, drug interactions, and short-term tolerabil-
ity/safety of bedaquiline. Current evidence of clinical efficacy
of bedaquiline is supported by data from phase II clinical trials,
primarily phase IIb studies. An overview of phase II studies is
provided in Table 3.
Phase IIa trials evaluated bactericidal activity in treatment-
naïve, sputum smear-positive pulmonary TB patients. A parallel-
group, open-label, randomized study assessed bedaquiline’s
EBA of three different doses of bedaquiline (25, 100, 400 mg)
compared to standard doses of rifampicin (600 mg q.d) and
isoniazid (300 mg q.d) in 75 subjects for 7 days. The primary
efficacy population was the intent-to-treat population. The bac-
tericidal activity of bedaquiline was confirmed based on the
reduction in CFU count over 7 days [12]. A second phase IIa,
two-center, open-label, randomized clinical trial evaluating pro-
mising new combinations of two new drugs, bedaquiline and
pretomanid, published recently demonstrated that this novel
combination together with pyrazinamide had activity similar to
that of the standard treatment regimen of HRZE over the first
14 treatment days. This was true with regard to both primary
end point of activity measured by the fall in CFU counts and
secondary end point determined by prolongation of time to a
positive signal. Estimated activities expressed by the daily rate
change in log10CFU of MTB were 0.167 (95% CI: 0.075–0.257) for
bedaquiline–pretomanid–pyrazinamide and 0.051 (95% CI:
0.071–0.232) for standard treatment. The study concluded that
bedaquiline–pretomanid–pyrazinamide is a potential new anti-
TB regimen containing two new drugs to which no resistance in
prevalent MTB strains is expected to exist [43]. However,
Mycobacterium canettii is intrinsically resistant to pyrazinamide
and might also be intrinsically resistant to pretomanid, leading
to potential of bedaquiline monotherapy [44].
Phase IIb included two studies, a randomized, double-blind,
placebo-controlled trial (C208) and an open-label single-arm
observational study (C209). C208 consisted of two studies;
stage 1 and stage 2, with two different panels of adult
patients, who had newly diagnosed pulmonary MDR-TB. All
subjects were sputum smear-positive, infected with MTB
strains resistant to at least both rifampicin and isoniazid.
Bedaquiline or placebo was added to a standard regimen for
MDR-TB. The primary efficacy end point was time to sputum
culture conversion in Mycobacteria Growth Indicator Tube
during the 8-week (stage 1) or 24-week (stage 2) investiga-
tional treatment period. In the exploratory trial (C208 stage 1),
23 patients received bedaquiline 400 mg daily for 2 weeks
followed by 200 mg 3 times weekly for 6 weeks, and 24
patients received placebo up to 8 weeks (in combination
with a background regimen). Following the 8-week trial per-
iod, patients continued their background regimen for a further
96 weeks [13]. At 4 weeks and at 8 weeks, the proportions of
patients with negative sputum smears were 77% and 84% for
the bedaquiline group and 57% and 68% for the placebo
group, respectively. As compared with placebo, at week 8,
the addition of bedaquiline to standard therapy for MDR-TB
reduced time to conversion to a negative sputum culture
(hazard ratio 11.8, 95%CI 2.3–61.3, P = 0.003). Bedaquiline
increased the proportion of patients with conversion of spu-
tum culture (48% vs. 9%) and declined rapidly the mean log10
CFU count in the sputum compared with the placebo [13]. At
24 weeks, efficacy was significantly better in the bedaquiline
group (hazard ratio 2.25, 95% CI 1.08–4.71, P = 0.031); 81% in
the bedaquiline arm and 65% receiving placebo were sputum
culture negative. Treatment success rates were similar at
104 weeks, 52.4% and 47.8% in the bedaquiline and placebo
arms, respectively. After week 24, 9.5% (bedaquiline, two sub-
jects) versus 17.4% (placebo, four subjects) of subjects were
considered to have had relapse [45]. The data showed the
potential of bedaquiline for MDR-TB, and this supported the
start of stage 2 of the trial.
In the C208 stage 2, which provides the pivotal data, 160
newly MDR-TB, smear-positive patients were randomized to
receive either 400 mg of bedaquiline once daily for 2 weeks,
followed by 200 mg 3 times weekly for 22 weeks, or placebo,
both in combination with a standard regimen. Patients were
followed for 120 weeks. At week 24, the median time to
sputum culture conversion was faster in the bedaquiline
group than in the placebo group (83 vs. 125 days,
P < 0.001). Bedaquiline increased the rate of culture conver-
sion at 24 weeks (79% vs. 58%, P = 0.008) and at 120 weeks
(62% vs. 44%, P = 0.04). On the basis of WHO definition, cure
rates at 120 weeks were 58% in the bedaquiline and 32% in
the placebo group (P = 0.003). Five subjects (7.6%) in the
bedaquiline group and eight subjects (12.1%) in the placebo
group experienced relapse [46].
The trial C209 was performed in 233 patients with newly
diagnosed MDR-TB or who previously failed treatment for
MDR-TB, including pre-XDR-TB (44 subjects) and XDR-TB (37
subjects). HIV-infected subjects could participate if their anti-
retroviral regimen could be switched to a triple nucleotide
reverse transcriptase inhibitor regimen, zidovudine, lamivu-
dine, and abacavir (trizivir), or if antiretroviral therapy could
be discontinued. Patient profiles were more like the typical
patient with MDR-TB than those in the C208 trials. The dose,
treatment, and follow-up duration are the same as in the C208
stage 2. After bedaquiline treatment, participants were fol-
lowed for a further 96 weeks during which the background
regimen was completed. Efficacy analysis was based on the
modified intention to treat population (n = 205) that excluded
patients with DS TB or patients with negative cultures at
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screening and/or baseline. The median time to culture conver-
sion was 57 days, which was shorter than the one in the C208
studies (83 days) because the majority of patients were receiv-
ing second-line therapy at baseline. Consistent with the C208
results, the sputum culture conversion rate was 79.5% at
24 weeks and 72.2% at 120 weeks, and it was 73.1%, 70.5%,
and 62.2% in patients with MDR-TB, pre-XDR-TB, and XDR-TB,
respectively. A percentage of 85.3 of 24-week responders were
still responders at 120 weeks. This showed that culture con-
version at 24 weeks was sustained and associated with a high
likelihood of response at 120 weeks, corroborating the obser-
vation that the 24-week culture conversion rate is predictive
for long-term MDR-TB treatment outcome. Seven patients
(3.4%) experienced relapse [26,47].
A pediatric phase II, multicenter, single-arm study has been
planned to evaluate the pharmacokinetics, safety, tolerability,
and antimycobacterial activity of bedaquiline in combination
with background regimen (ClinicalTrials.gov identifier:
NCT02354014). Furthermore, a randomized, open-label phase
II trial evaluating the safety, tolerability, and pharmacokinetics
of bedaquiline and delamanid, alone and in combination, for
drug-resistant pulmonary TB is also planned but not yet open
for recruitment (ClinicalTrials.gov identifier: NCT02583048).
8.2. Phase III studies
Currently, several phase III trials are ongoing that may con-
firm the efficacy findings from phase II trials and provide
additional safety data. A phase III study assessing the safety
and efficacy of bedaquiline plus pretomanid plus linezolid in
patients with drug-resistant pulmonary TB is now recruiting
patients with a planned enrollment of 200 subjects
(ClinicalTrials.gov identifier: NCT02333799). Furthermore, an
open-label, randomized, placebo-controlled trial is also
recruiting participants to evaluate a new treatment regimen
of linezolid, bedaquiline, levofloxacin, pyrazinamide, and
ethionamide/high-dose isoniazid compared to the conven-
tional empiric injection-based regimen of 21–24 months
treatment for patients with MDR-TB (ClinicalTrials.gov iden-
tifier: NCT02454250). The evaluation of a standard treatment
regimen of anti-TB drugs including locally used WHO-
approved MDR-TB regimen, moxifloxacin, clofazimine,
ethambutol, pyrazinamide, isoniazid, prothionamide, kana-
mycin, levofloxacin, and bedaquiline for patients with MDR-
TB is planned but not yet open for participant recruitment
(ClinicalTrials.gov identifier: NCT02409290).
8.3. Experience from compassionate use
Based on analyses of interim results of trial C208 stage 2,
bedaquiline was made available for compassionate use in
2011. The first evidence on the compassionate use of bedaqui-
line to treat MDR/XDR-TB cases was the management of two
XDR-TB patients with bedaquiline at the Italian TB Reference
Centre [48]. After achieving culture conversion after 2 months
(58 and 63 days) on linezolid, meropenem, and amoxicillin/
clavulanate, the patients were exposed to bedaquiline for a
total of 180 days without major AEs. Both subjects achieved
consistent bacteriological conversion and radiological
improvements and then moved to the continuation phase of
treatment with a plan to continue for 24 months [48]. Data on
bedaquiline use in 91 XDR-TB patients from the Expanded
Access Programme in South Africa showed 76% of patients
with sputum culture conversion or persistently negative cul-
tures observed at 6 months [49]. A recent interim analysis of
compassionate use of bedaquiline in 35 MDR-TB subjects
showed that after 6 months of bedaquiline treatment, sputum
culture conversion was observed in 28 of 29 (97%) patients
who were culture positive initially and the median time to
sputum culture conversion was 85 (8–235) days. Only two
patients needed to stop bedaquiline during the course of
therapy [50]. The use of bedaquiline in a series of five Indian
XDR-TB patients also showed striking improvement, with
microbiological conversion [51]. The use of bedaquiline as a
substitute for linezolid in the first XDR-TB case in the US was
reported to allow the successful completion of adequate XDR-
TB therapy with good tolerability and a favorable outcome
10 month after the treatment completion [52].
In a case report on a pericardial XDR-TB patient receiving
bedaquiline at week 14 when full drug sensitivity testing
became available for 24 weeks, culture negative was remained
at the end of her planned 2-year treatment regimen with no
specific AEs [53]. Bedaquiline treatment for 18 months was
reported firstly in one XDR-TB patient and showed no recur-
rence of sputum smear or culture positivity, gradual weight
gain, and resolution of active inflammatory changes on serial
CT scans and the patient was graded as cured [54].
9. Safety and tolerability
The phase IIb trial data were pooled to increase the likelihood
of detecting AEs due to higher number of subjects per pooled
treatment group and to increase sample size for subgroup
analyses. The most frequently reported AEs in the pooled
bedaquiline (Any bedaquiline) group (>20.0% of subjects)
were nausea (35.3%), arthralgia (29.4%), headache (23.5%),
hyperuricemia (22.5%), and vomiting (20.6%). Most AEs were
grade 1 or 2 in severity. The incidence of grade 3 or 4 AEs was
27.5% in the Any bedaquiline group and 22.9% in the pooled
placebo (Any placebo) group. Hyperuricemia was the most
frequently reported grade 3 or 4 AE, which occurred in
10.8% of participants in the Any bedaquiline group and
13.3% in the Any placebo group. Other grade 3 or 4 AEs
were reported in <3.0% of subjects in both groups. A higher
incidence of serious AEs was observed in the Any bedaquiline
group, with seven (6.9%) subjects compared to two (1.9%)
subjects in the Any placebo group. However, the overall num-
ber of AEs leading to permanent discontinuation was low and
balanced in both groups [26]. AEs of interest included AEs
related to the liver, pancreas, QT prolongation, muscle, and
skin. The number of patients with AEs related to skeletal,
muscle, pancreas, and stomach was similar in both groups.
9.1. Prolongation of corrected QT interval
Bedaquiline prolongs corrected QT (QTc) interval. No Torsade
de Pointes events and no fatalities from sudden death were
reported. The pooled analysis of C208 trials showed that mean
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QTc increased in both pooled groups, but mean increases
were more pronounced in the Any bedaquiline group and
observed from the first assessment after Day 1 onward.
Increase in QTc became gradually larger over the first
8 weeks of taking bedaquiline and then remained stable
until week 24. Over 24 weeks of bedaquiline treatment,
mean increase in QTc was 15.4 ms compared to 6.2 ms in
the placebo group and it became less pronounced after
24 weeks of bedaquiline dosing period [26].
The safety finding in the C209 trial revealed that increases
in QTc were larger in patients receiving concomitant clofazi-
mine (n = 17) than those without concomitant clofazimine use
(n = 177) [47]. Mean increase in QTc from baseline was also
previously reported to be larger in patients receiving bedaqui-
line in combination with clofazimine than in those receiving
only bedaquiline, although this was not associated with clini-
cally relevant arrhythmias [55]. QTc > 500 ms was observed in
two subjects, both of whom recieved clofazimine. The QTc was
between 450 and 500 ms for 22.5% of patients taking beda-
quiline and 6.7% of patients taking placebo. The maximum
change in QTc from baseline was 14.2 ms and this decreased
to <10 ms after stopping bedaquiline [47].
When bedaquiline is given with other QT-prolonging anti-TB
drugs, the effect on the QT interval could be additive, compli-
cating efforts to optimize multidrug treatment for MDR-TB.
Pyrazinamide, moxifloxacin, and clofazimine can potentially
cause QT prolongation as well. In a study evaluating the com-
bination of bedaquiline, pyrazinamide, and clofazimine, an
increase from baseline of ≥60 ms in QTc was reported for two
patients (13.3%) and no QTc ≥ 500 was reported. However, QT
prolongations remained within acceptable safety limits [43].
In addition, coadministration of verapamil with bedaquiline
is a promising strategy not only for improving MDR-TB treat-
ment efficacy and reducing bedaquiline dosing, but also for
reducing the risk of QTc prolongation. Verapamil, which has
effects of extending the PR interval and reducing the QTc
interval, has been shown to be able to limit or even abrogate
the negative cardiac effects of bedaquiline [56].
The report on compassionate use of bedaquiline was in two
XDR-TB patients for 6 months and reported no QTc prolongation
[48]. An absence of notable adverse effects such as prolonged
QTc was also noted in five IndianMDR/XDR-TB patients receiving
bedaquiline [51]. During the bedaquiline treatment under com-
passionate use in 35 French MDR-TB patients, the QTc interval
increased by a median of 1.96 ms (range, −64–71 ms). Overall,
increases of QTc ≥ 60 ms from baseline were observed in 20% of
patients and three (9%) patients had a QTc value >500 ms.
Bedaquiline was discontinued in two (6%) patients due to per-
sistent QTc prolongation. No cardiac arrhythmia was documen-
ted [50]. In the interim analysis of 91 XDR-TB patients in the
South African Bedaquiline Clinical Assess Programme, of whom
54 were HIV infected and all were on antiretroviral treatment at
bedaquiline initiation, QTc was monthly monitored and
exceeded 500 ms in 3 patients. Bedaquiline was temporarily
withdrawn in one patient; in all three, the QTcF decreased to
below 500 ms and there were no clinical sequelae. Atrial fibrilla-
tion while on bedaquiline was developed in one patient, leading
to the discontinuation of the drug [49].
9.2. Hepatic events
The pooled data analysis of C208 studies revealed that higher
incidence of hepatic events was observed in the Any bedaqui-
line group compared to the Any placebo group (8.8% vs. 1.9%,
P = 0.03). Transaminases increased in the majority of these
reported events of which all but two resolved. One patient
met the laboratory criteria for Hy’s law at week 32 (treatment-
emergent serum alanine aminotransferase [ALT] or aspartate
aminotransferase (AST) >threefold upper limit of normal [ULN]
with serum total bilirubin >2 times ULN and recovered, but
this was confounded by reported alcoholic hepatitis and con-
current intake of hepatotoxic background medications [includ-
ing paraaminosalicyclic acid and ethionamide]) [26,47]. In a
detailed analysis over 120 weeks in the single-arm C209, four
(1.7%) patients were identified to have hepatic events related
to bedaquiline. One of these four did not resolve, but the
patient also had hepatitis C infection. One patient had grade
≥3 hepatic-related AEs due to bedaquiline use [47]. Permanent
discontinuation of bedaquiline due to bedaquiline-related
hepatic disorders was documented in three (2.9%) patients
in the Any bedaquiline group. In the C208 stage 2 trial, one
patient receiving bedaquiline died due to hepatitis/hepatic
cirrhosis [26].
The study on compassionate use of bedaquiline in a French
cohort of 35 MDR-TB patients reported that mild liver enzyme
AST/ALT elevation (≥twofold baseline) occurred in 5 (14%)
patients. Severe liver enzyme elevation (≥fivefold baseline),
confounded by the concomitant use of hepatotoxic com-
pounds (pyrazinamide, fluoroquinolones, and para-aminosa-
licylic acid), occurred in two additional patients (6%) and did
not lead to bedaquiline discontinuation. In these two patients,
liver enzymes peaked after 3 months of bedaquiline treatment
and reverted to normality during the subsequent month [50].
No hepatotoxicity was reported as a severe AE in 91 pre-XDR-/
XDR-TB patients in the South Africa Bedaquiline Clinical Access
Programme treated with bedaquiline and antiretroviral
drugs [49].
9.3. Death
In the trial C208 stage 1, two patients died in the bedaquiline
group (one died during the trial and one died after withdraw-
ing prematurely) and two patients died in the placebo group
(both died after withdrawing prematurely) [26].
In the trial C208 stage 2, 10 deaths occurred in the beda-
quiline group and 2 deaths in the placebo group [46]. TB was
the cause of death in 5 of the 10 bedaquiline deaths and both
placebo deaths. Of 10 deaths in the bedaquiline arm, 4 deaths
occurred during long-term survival follow-up of premature
withdrawals. No deaths were considered to be related to
bedaquiline in both stages of the trial C208. The reason for
the imbalance in death between the two arms in the second
stage is unclear [46].
Amongst 233 participants in the trial C209, 16 deaths
(6.9%) were reported by the trial cutoff date (120 weeks), 4
of which occurred after withdrawal from the study. Of the 12
remaining deaths, 3 occurred during the bedaquiline treat-
ment and 9 during the 96-week follow-up period. TB-related
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diseases were causes of death in 11 patients (68.8%). None of
deaths were related to bedaquiline, exept for renal impair-
ment that was judged doubtfully related to bedaquiline
[26,47].
In the compassionate access cohorts, 3 deaths were
reported in the South African Bedaquiline Clinical Access
Programme [49] and 1 death was reported in the French
cohort of 35 MDR-TB patients but none of them were consid-
ered to be related to bedaquiline [50].
10. Cost-effectiveness
The cost-effectiveness of introducing bedaquiline in MDR-TB
treatment regimens in six low- and middle-income countries
(Russia, Estonia, Philippines, Peru, Nepal, and China) was
assessed by the WHO, using outcomes from published litera-
ture and initial results from bedaquiline clinical trial program
[57]. It was concluded that bedaquiline is highly likely to be
cost-effective in most environments, with cost-savings in
environments which have high MDR-TB treatment costs [57].
In high-income countries, patients are almost always hos-
pitalized with lengthy period of hospital stay and incur sig-
nificant costs to health-care systems. Wolfson et al. developed
a comprehensive model looking at cost-effectiveness of beda-
quiline plus background regimen in the United Kingdom and
reported that bedaquiline is likely to be cost-effective and
cost-saving, compared with the current MDR-TB standard of
care [58]. This was also confirmed in a recent study examining
cost-effectiveness of bedaquiline in the German health-care
system [59].
11. Regulatory affairs
Bedaquiline is the first new anti-TB drug to be introduced into
the market in more than 40 years. The approval of the US FDA
and the European Medical Agency was based on results of
phase IIb clinical trials. Due to QTc prolongation and signifi-
cant excess mortality, the FDA required a black-box warning
on the bedaquiline package insert [60]. A phase III multicenter,
randomized, double-blind, placebo-controlled trial of bedaqui-
line in subjects with sputum smear-positive pulmonary MDR-
TB was required to confirm efficacy findings from phase II trials
and provided additional evidence on safety of bedaquiline
and it was initially scheduled to start recruiting subjects in
2013.
Because no phase III trial has been completed, the potential
interim guidance issued by WHO [3] is provisional until further
efficacy and safety data, particularly from phase III trial,
become available. The WHO document specified the essential
conditions for the bedaquiline use and is targeted at national
TB programs, public health agencies, as well as public and
private partners involved in planning, implementing, and
monitoring MDR-TB control activities. A WHO implementation
plan has been developed to assist countries in the preparation
and conduct of necessary activities for the introduction of
bedaquiline [61].
12. Conclusion
Bedaquiline, a new anti-TB drug, belongs to the diarylquinoline
family and has an appealingly novel action mechanism. Its
recommended dosing regimen is 400 mg daily for 2 weeks
and then 200 mg thrice weekly for a total of 6 months. Its
long half-life will increase the risks of acquired bedaquiline
resistance if drugs are discontinued or have mismatched half-
lives and long dosing interval [60]. Though bedaquiline has
shown excellent efficacy in phase II clinical trials, its EBA during
the first week of chemotherapy is minimal. There was a linear
increase in bactericidal activity with increasing dose over
14 days of treatment. The predominant AEs included hepatic
disorders and cardiac QTc prolongation. The risk of QTc prolon-
gation could be additive when bedaquiline is coadministered
with other QTc prolonging medications. In addition, conditions
and medications associated with hepatotoxicity could pose
additional hepatotoxic risks in patients receiving bedaquiline.
This suggests careful monitoring, particularly in patients with
preexisting liver disease and/or regular alcohol use. The death
rate in the group of patients receiving bedaquiline in the phase
IIb trial was 5 times higher than among patients who did not
receive bedaquiline (10 of 79 vs. 2 of 81 patients) but the
reasons for this remain unclear, resulting in a black-box warning
on its label and raising concerns about drug safety. Mortality
related to bedaquiline use needs to be further investigated.
Additionally, caution should be paid when bedaquiline is used
in combination with antiretroviral drugs due to potential drug
interactions. Coadministration of bedaquiline with rifampicin or
other potent CYP3A4 inducers is not recommended due to the
risk of reduced plasma concentration of bedaquiline. A few
studies reported clinical evidence on efficacy and safety of
bedaquiline in non-trial settings as part of compassionate use
or expanded access programs. Overall, bedaquiline was well
tolerated and safe. The high rate of culture conversion and the
low mortality rate in these cohorts are promising findings, high-
lighting the potential of bedaquiline to improve outcome in
patients with MDR or XDR-TB. However, it is premature to
make any conclusions on the efficacy of bedaquiline as part of
combination therapy for MDR-TB treatment. Critical safety data
for bedaquiline are incomplete. Well-designed, randomized stu-
dies in large populations are required to confirm effectiveness
findings and provide additional long-term safety data for
bedaquiline.
13. Expert commentary
Given the emergence of MDR-TB, with the challenge of limited
treatment options and low cure rates, it is crucial to develop
new, shorter, and safer treatment regimens. To obtain success,
the development of new anti-TB drugs with novel mechan-
isms of action and activity against drug-resistant TB is urgently
required. The introduction of bedaquiline into the treatment
regimens for MDR-TB represents considerable progress in
research and drug development of new anti-TB drugs.
Findings reported in clinical trials demonstrated improved
efficacy with the addition of bedaquiline when compared to
standard therapy alone for MDR-TB. It should be noted that
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the approval of bedaquiline was based on trials that evaluated
using the surrogate marker of culture conversion rather than the
gold standard of durable cure after completion of therapy [62].
The primary end point of time to culture conversion may predict
non-relapsing cure in clinical trials of DS TB [63] but has poor
prognostic value at individual patient level and has not been
validated for MDR-TB patients [64]. The scarcity of current clinical
evidence supports the cautious use of bedaquiline. Before results
from phase III studies are published, efficacy and safety data
could be collated from compassionate studies. Currently, cohorts
of pre-XDR or XDR-TB patients are collected in high-burden
countries under five conditions recommended by interim WHO
guidance including strict pharmacovigilence monitoring. Once
data from those cohorts are integrated, more consolidated con-
clusions on the role of bedaquiline can be obtained.
Ideally, drug approvals should be based on evidence col-
lected from large randomized studies measuring actual clinical
outcomes. Nevertheless, the pivotal data on bedaquiline were
reported in limited studies with small sample sizes. The acceler-
ated approval from the FDA was based solely on 2 phase IIb
studies of 440 MDR-TB patients. Thus, critical data for long-term
efficacy and safety are needed for bedaquiline as for many other
antimicrobial drugs that used for MDR-TB treatment.
14. Five-year review
Until further research evidence is available, the use of beda-
quiline must be carefully controlled to prevent the spread of
drug resistance and closely monitored for AEs and drug inter-
actions. In the future, studies on bedaquiline should focus on
various combination therapies with new and existing drugs to
shorten MDR/XDR-TB treatment.
Key issues
● Bedaquiline is a new anti-tuberculosis (TB) drug and
approved as part of combination therapy in pulmonary multi-
drug resistant tuberculosis (MDR-TB) by the US FDA in 2012.
● Bedaquiline has a new mechanism of action: inhibition of
mycobacterial ATP synthetase, resulting in depletion of
cellular energy stores.
● Bedaquiline has a very long half-life, however it takes
4–7 days for onset of bactericidal activity
● Evidence from phase II trials showed that bedaquiline was
well tolerated and had good efficacy when being used
along with a background regimen for MDR-TB.
● There are two important black box warnings for this drug:
prolongation of QT interval and increased mortality with
bedaquiline as compared to placebo treatment.
● Given incomplete and scarce data, phase III trials are cur-
rently ongoing to confirm safety and efficacy findings from
phase II studies.
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